Micropakine L.P. (Valproic Acid, Sodium Valproate)

Micropakine L.P. (valproic acid) is used in several neurological and psychiatric conditions where modulation of neuronal excitability is required.

• Epilepsy: reduces the frequency, duration, and severity of both focal and generalized seizures, helping patients achieve better seizure control and improved quality of life.
• Bipolar disorder: stabilizes mood by preventing manic highs and depressive lows, decreasing hospitalization rates and supporting long‑term maintenance therapy in affected individuals.
• Migraine prophylaxis: lowers the monthly migraine attack count, reduces attack severity, and diminishes associated nausea and photophobia, thereby enhancing daily functioning.

• Valproic acid increases brain concentrations of the inhibitory neurotransmitter gamma‑aminobutyric acid (GABA) by inhibiting GABA transaminase and enhancing its synthesis. It also blocks voltage‑gated sodium channels, reducing neuronal firing, and modulates glutamate neurotransmission through inhibition of NMDA receptor activity. These combined actions stabilize neuronal membranes and suppress hyper‑excitability. Additionally, valproic acid influences histone deacetylase activity, contributing to gene expression changes that support its antiepileptic effects.

Valproic acid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea or vomiting: may occur especially after initiating therapy or dose escalation.
• Tremor or dizziness: often mild and transient, but can affect coordination.
• Weight gain or increased appetite: gradual increase in body weight may be observed over time.

Serious or Rare Side Effects

• Severe liver injury or hepatitis: presents with jaundice, elevated enzymes, and can be life‑threatening.
• Pancreatitis: characterized by abdominal pain, elevated lipase, and may require hospitalization.
• Blood dyscrasias such as thrombocytopenia or leukopenia: result in abnormal bleeding or susceptibility to infection.

When prescribing valproic acid, clinicians should observe several precautionary measures to ensure patient safety.

• Liver function monitoring: assess baseline enzymes and repeat periodically during treatment.
• Pregnancy risk counseling: discuss teratogenic potential and consider alternative therapies for women of childbearing potential.
• Concomitant medication review: avoid drugs that impair hepatic metabolism or increase valproate levels.
• Hematologic surveillance: monitor complete blood count for signs of thrombocytopenia or leukopenia.
• Renal function assessment: adjust dosing in patients with significant renal impairment.
• Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and direct sunlight.

Valproic acid interacts with several medicines, influencing its plasma concentration and therapeutic effect.

Major Interactions (Avoid)

• Carbamazepine: induces hepatic enzymes, markedly reducing valproate levels.
• Phenobarbital: accelerates valproic acid metabolism, compromising seizure control.
• Rifampicin: strong enzyme inducer that can lead to subtherapeutic valproate concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: valproate may increase anticoagulant effect, requiring INR monitoring.
• Lamotrigine: co‑administration can raise lamotrigine levels, increasing risk of rash.
• Oral contraceptives: valproate may reduce hormonal efficacy, necessitating alternative contraception.